About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cytodyn Inc (OP:CYDY)

0.2275 +0.0005 (+0.22%)
Streaming Delayed Price Updated: 12:05 PM EDT, Mar 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cytodyn Inc

< Previous 1 2 3 4 5 Next >
News headline image
CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer
From CytoDyn Inc.
Via GlobeNewswire
News headline image
December 2025 Letter to Shareholders
From CytoDyn Inc.
Via GlobeNewswire
News headline image
A Penny Stock To Watch In Challenging Cancer Space ↗
The author has a $2.75 Price Target on CytoDyn (CYDY) in the Next 6 to 12 months, representing significant upside from its current price of around $0.32. 
Via Benzinga
News headline image
CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Announces Resolution of Class Action Lawsuit
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn to Present Prolonged Survival Data on Leronlimab in Metastatic Triple-Negative Breast Cancer at the San Antonio Breast Cancer Symposium
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Secures $30 Million Commitment from Yorkville Advisors
From CytoDyn Inc.
Via GlobeNewswire
News headline image
Halper Sadeh LLC Encourages CytoDyn Inc. Shareholders to Contact the Firm to Discuss Their Rights
From Halper Sadeh LLC
Via Business Wire
News headline image
CytoDyn to Present at the LD Micro Main Event XIX Investor Conference
From CytoDyn Inc.
Via GlobeNewswire
News headline image
September 2025 Letter to Shareholders
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn to Present on Leronlimab Induction of PD-L1 and Immune Checkpoint Inhibitor Responses in Metastatic Triple-Negative Breast Cancer at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn to Present at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn to Present at the H.C. Wainwright 27th Annual Global Investment Conference
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Announces Encouraging Survival Data in Patients with Metastatic Colorectal Cancer Previously Treated with Leronlimab
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer
Enrollment is now underway across multiple clinical sites, in partnership with Syneos Health 
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Releases ESMO Breast Cancer Meeting Poster
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Announces Data Suggesting Novel Mechanism of Action of Leronlimab for the Treatment of Solid Tumors
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Leadership Team To Attend ESMO Breast Cancer Meeting in Munich, Germany
From CytoDyn Inc.
Via GlobeNewswire
News headline image
When Penny Stocks Can Become Compelling: A Long-Term Buy With CYDY ↗
CytoDyn represents a speculative bet on a once-celebrated drug that is now steadily rebuilding its case. If leronlimab can fulfill its early promise in metastatic triple-negative breast cancer, the... 
Via Talk Markets
Topics Stocks / Equities
News headline image
FDA Advisory Committee Shakeup and Implications for Capricor Therapeutics ↗
Don't be scared off up by the recent Trump FDA overhaul. The changes are very positive for Capricor Therapeutics moving forward (2025–2028). 
Via Talk Markets
Topics Government Stocks / Equities
News headline image
March 2025 Letter to Shareholders
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Announces Promising Survival Observations in mTNBC Patients Treated with Leronlimab
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Announces Findings of Statistically Significant Fibrosis Reversal Across Studies with SMC Laboratories
From CytoDyn Inc.
Via GlobeNewswire
News headline image
December 2024 Letter to Shareholders
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Appoints Richard Pestell, M.D., Ph.D. as Lead Consultant in Oncology
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Announces FDA Clearance of Its Phase II Oncology Trial
From CytoDyn Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.